Hindustan Unilever Ltd (HUL) on Thursday said its foods business remains “an important and attractive segment” and clarified that it is “not in any discussions regarding divestment of the Foods portfolio" in a stock exchange filing responding to global reports of a potential restructuring at parent Unilever Plc.The clarification shared with BSE comes after a Bloomberg report said Unilever was exploring a separation of its foods portfolio—potentially through a spin-off or partial divestment—as it sharpens it ...

Core Insights - G-III Apparel Group, Ltd. reported disappointing fourth-quarter fiscal 2026 results, with both net sales and earnings falling short of the Zacks Consensus Estimate, reflecting a year-over-year decline [1][5] Financial Performance - Adjusted earnings per share (EPS) were 30 cents, missing the Zacks Consensus Estimate of 57 cents, and decreased by 76.4% from the previous year's earnings of $1.27 per share [5] - Net sales fell 8.1% year over year to $771.5 million, also below the consensus estimate of $794 million, with approximately $20 million in lost sales attributed to the suspension of shipments to Saks prior to its bankruptcy [5][6] - The wholesale segment generated net sales of $737 million, missing the Zacks Consensus Estimate of $747.1 million, and reflecting a 7.8% decrease from the prior year [6] - The retail segment's net sales were $63 million, meeting the consensus estimate and representing a 12.5% increase compared to $56 million in the prior-year quarter [7] Margins and Expenses - Gross profit decreased 13.9% year over year to $285.5 million, with a gross margin of 37%, down 250 basis points year over year, primarily due to tariffs [8] - Adjusted SG&A expenses totaled $260 million, reflecting a 6.6% increase, which included a $17.5 million bad debt expense related to the Saks bankruptcy [9] - SG&A expenses as a percentage of net sales increased by 470 basis points year over year to 33.7% [10] Financial Position - G-III Apparel ended the fiscal fourth quarter with cash and cash equivalents of $406.7 million and long-term debt of $11.7 million, with total stockholders' equity at $1.76 billion [11] - Inventory increased by 3.8% year over year to $460 million at the end of the quarter [11] Future Outlook - For the first quarter of fiscal 2027, the company expects net sales of approximately $530 million, a 9.2% decline year over year, and anticipates a net loss between $13 million and $18 million [12] - For fiscal 2027, G-III expects net sales of approximately $2.71 billion, an 8% decline compared to fiscal 2026, primarily due to lost sales from Calvin Klein and Tommy Hilfiger products [14] - Expected net income for fiscal 2027 is projected to be between $88 million and $92 million, with EPS of $2.00 to $2.10, indicating a year-over-year increase in net income [15] - The company anticipates gross margin improvement of up to 300 basis points for the full fiscal year, supported by tariff mitigation efforts [20]

Core Viewpoint - Ampco-Pittsburgh Corporation has shown significant stock performance, with a 253.9% increase over the past three months, outperforming both the industry and broader market indices [1][7]. Financial Performance - The company announced promising third-quarter 2025 results, showcasing year-over-year revenue growth and improved core profitability, driven by strong demand in the Air and Liquid Processing (ALP) segment and favorable pricing [2][12]. - Management noted stable demand across major end markets and improving supply-chain conditions, which are expected to enhance profitability in the future [3]. Market Position and Strategy - Ampco-Pittsburgh operates through the Forged and Cast Engineered Products (FCEP) and ALP segments, serving diverse global markets including industrial, energy, nuclear, and manufacturing [9]. - Recent portfolio restructuring, including exiting unprofitable operations, is anticipated to significantly improve adjusted EBITDA and streamline operations, positioning the company for stronger profitability [10][11]. Segment Performance - The ALP segment achieved its best year-to-date performance in Q3 2025, with increased revenues and an improved product mix, indicating durable demand trends in energy and defense markets [12][13]. Competitive Landscape - The company holds a strong leadership position in forged and cast rolls, with significant market share in North America and Europe, supporting pricing resilience [13]. Challenges - Ampco-Pittsburgh faces cyclical softness and excess capacity in the global steel industry, which may pressure demand and create pricing volatility [14]. - Ongoing trade policy uncertainty and tariffs have led to order delays and inventory adjustments, impacting normal purchasing patterns [14]. Valuation - The company's trailing 12-month EV/Sales ratio of 0.7X is below the industry average of 1.9X, suggesting that the market may not fully reflect its improving fundamentals [15][18]. Outlook - The company appears well-positioned for future growth, supported by operational improvements and a streamlined portfolio, despite broader industry challenges [17][20].

Core Insights - The strong performance in 2025 was attributed to high patient acuity, a favorable payer mix, and effective financial controls across the portfolio [1] Financial Performance - Same-unit pricing growth was just under 7%, driven by improved revenue cycle management (RCM) cash collections and increased contract administrative fees [1] - Volume declines of approximately 3% in the fourth quarter were due to challenging year-over-year comparisons rather than a fundamental shift in demand [1] Operational Strategies - Management introduced two new physician alignment programs, including stock-price tracking grants, aimed at enhancing clinician retention and operational accountability [1] - Portfolio restructuring activities successfully reduced practice-level salary and benefit expenses, which helped offset same-unit inflationary pressures [1] Market Positioning - The company is leveraging its dominant position in level three and level four NICUs to capture higher-acuity cases that require specialized clinical capabilities [1] - Strategic investments in leadership and clinical quality are prioritized to maintain the company's competitive advantage in neonatology and obstetrics [1]

Core Viewpoint - JX Advanced Metals' subsidiary Pan Pacific Copper has sold its entire stake in Compañía Minera Quechua to Glencore Peru Holding, allowing Glencore to take over the Quechua copper project and enabling JX to reallocate resources to align with its long-term strategy [1][3][5]. Group 1: Transaction Details - JX Advanced Metals holds a 47.8% ownership stake in Pan Pacific Copper, which has sold all issued shares of Compañía Minera Quechua to Glencore Peru Holding [1]. - Following the sale, Glencore will control all mining interests in the Quechua copper project, which PPC has evaluated since acquiring interests in 2007 [1][2]. - PPC deferred development of the Quechua project to prioritize the Caserones copper and molybdenum project and due to challenges in independent development [2]. Group 2: Strategic Implications - The sale allows JX Advanced Metals and its equity partners to reallocate resources to initiatives that align with their individual policies [3]. - JX Advanced Metals is rapidly expanding its Focus Businesses in the advanced materials sector while optimizing its Base Businesses in mineral resources, metals, and recycling [3][4]. - The company aims to strengthen supply chains for copper and minor metals and curb volatility through portfolio restructuring in its Mineral Resources segment [4][5]. Group 3: Production Adjustments - In September, it was reported that JX Advanced Metals plans to reduce its copper production by several tens of thousands of tonnes in fiscal year 2025 compared to previous projections [6].

Financial Data and Key Metrics Changes - The adjusted EBITDA for Q3 2025 was $87 million, exceeding expectations, with a full-year adjusted EBITDA outlook of $270-$290 million [4][6] - Consolidated revenue decreased by just under $54 million due to portfolio restructuring, partially offset by strong same-unit growth of 8% and same-unit pricing up about 7.5% [6][8] - Operating cash flow generated in Q3 was $138 million, compared to $96 million in the prior year, driven by higher earnings and increased cash flow from accounts receivable [8][9] Business Line Data and Key Metrics Changes - Same-unit pricing increase was driven by solid revenue cycle management (RCM) cash collections, increased patient acuity in neonatology, and an increase in contract administrative fees [6][28] - Salary growth for the third quarter was modestly below the previous five-quarter average of 3-3.5% [7] - A net gain on investments in divested businesses was $21 million, contributing to other non-operating income [7] Market Data and Key Metrics Changes - The company maintained a strong market position with over 1,300 physicians and 1,170 advanced practice providers across 322 locations in 33 states [11] - The company has a comprehensive clinical data warehouse with 37 million patient days and 2 million NICU admissions, supporting its research productivity [11] Company Strategy and Development Direction - The company is focused on enhancing technological support and has developed a proprietary system called BabySTEPS to assist clinicians in caring for high-risk NICU patients [12][13] - The company aims to strengthen its operations in pediatric surgery, neurology, and cardiac intensive care, while continuing to build partnerships with hospital systems [16][41] Management's Comments on Operating Environment and Future Outlook - Management acknowledges significant healthcare headwinds but sees many opportunities to strengthen operations and results [17] - The company is optimistic about the potential benefits of exchange credits for expecting mothers, although the exact impact remains uncertain [37] Other Important Information - The company repurchased 1.2 million shares in the quarter, totaling 1.7 million shares to date [4] - The company ended the quarter with cash of $340 million and net debt of just over $260 million, reflecting a net leverage of just under one times [9] Q&A Session Summary Question: Thoughts on capital deployment and share repurchase - Management has been aggressively buying back shares and is exploring various opportunities for growth, both internally and externally [20] Question: Impact of portfolio restructuring on market dynamics - Management believes the restructuring has strengthened the company’s focus and improved the environment for recruiting new practices [21][22] Question: Breakdown of strong pricing in the quarter - Strong pricing was driven by RCM collections, increased acuity, and contract administrative fees, with expectations for stability in payer mix [27][28] Question: Guidance on seasonality and volume factors - Management indicated that there are no significant changes in volumes expected, but variability may arise as the year ends [30][31] Question: Long-term outlook and potential opportunities - Management is optimistic about future partnerships with hospital systems and believes financial strength will provide additional opportunities [38][40]

Financial Data and Key Metrics Changes - The company reported adjusted EBITDA of $69 million for Q4 2024, significantly exceeding previous guidance [10] - Consolidated revenue growth was just over 1%, with same unit growth of 8.7%, primarily offset by the impact of portfolio restructuring [18] - Operating cash flow for Q4 was $135 million, compared to $73 million in the prior year, with a reduction in net debt from $515 million to $386 million [21][23] Business Line Data and Key Metrics Changes - The company completed a portfolio restructuring, exiting practices that represented $200 million in annual revenue, which was a drag on earnings [10] - The decline in practice-level expenses reflected the restructuring, with same unit salary expense growth remaining above the historical range of 2% to 3% [20][31] Market Data and Key Metrics Changes - The payer mix was a significant positive factor in 2024, contributing to strong operating results, although it is not expected to change significantly in 2025 [30][61] - The company anticipates flat volume in its 2025 outlook, despite some acceleration in the latter half of 2024 [37][38] Company Strategy and Development Direction - The company aims to prioritize patient-centric care, strengthen hospital relationships, and manage its improved financial position effectively [13][14] - A preliminary expectation for adjusted EBITDA in 2025 is set between $215 million and $235 million, reflecting a cautious outlook due to uncertainties in the healthcare provider space [14][17] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's prospects despite acknowledging headwinds in the healthcare sector [17] - The focus for 2025 includes maintaining stability in the revenue cycle management (RCM) process and seeking improvements through automation [29] Other Important Information - The company ended 2024 with cash of $230 million and plans to build cash again in 2025 [23][24] - The impact of the portfolio restructuring is expected to provide an annualized EBITDA benefit of approximately $30 million, with a third realized in 2024 [27][81] Q&A Session Summary Question: Can you provide more details on the 2025 outlook? - Management indicated that they are baking in flat volume growth and stable pricing expectations for 2025, with a focus on maintaining performance under the hybrid RCM model [36][40] Question: Are there opportunities for improved economics in NICU management? - Management confirmed ongoing discussions with hospital partners but did not incorporate any increases into their forecast [44] Question: How much of the strong pricing in Q4 came from improvements in contract admin fees? - Approximately one-third of the pricing component was attributed to hospital admin fees [75] Question: What is the expected EBITDA tailwind from exiting primary and urgent care clinics? - The exit is part of a broader restructuring, with about a third of the expected $30 million EBITDA benefit realized in 2024 and the remainder anticipated in 2025 [81] Question: What are the company's plans for capital allocation and returning cash to shareholders? - The company is focused on maintaining a strong balance sheet and will evaluate the best uses of cash, including potential debt repayment or shareholder returns [88][90]